Top Data Analytics Companies in Boston, MA (147)

Strong Revenue Growth: Revenue is accelerating, with FY2025 up 19% year over year and Q4 2025 up 22%, followed by Q1 and Q2 2026 growth of 22% and 27%. Guidance for 2026 was raised to $94–$96 million, implying 22%–24% growth.

Strategic Partnerships: Collaborations with Mount Sinai (April 2026), Memorial Sloan Kettering (June 2026 precision medicine hub), and an expanded AstraZeneca alliance (August 2025) are highlighted as supporting platform adoption and data generation. Several large BioPharma contracts signed into late 2025/early 2026 further reinforce traction.

Customer Loyalty & Retention: Spending within the installed base is rising, with net dollar retention improving to 115% in 2025 and 117% in the first quarter of 2026. This coincides with rising analysis volumes across 2025–2026.

Strategic Partnerships: Partnerships with Quest Analytics (June 16, 2025) and collaborations such as with the American College of Surgeons, alongside a growing Aggregate user conference in 2025–2026, align with commercial momentum. Announced marketplace additions and ecosystem integrations further point to an expanding partner network.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in July 2025 to support a “next phase of growth,” building on a $125 million financing from Vista Credit Partners in 2023. These moves signal access to capital to scale the platform and accelerate expansion.

Product Line Growth: A next‑gen lakehouse‑based data platform launched in February 2024 and subsequent 2025–2026 AI/interoperability capabilities—building on the CareJourney acquisition—indicate continued product expansion. New solutions such as Network Modeler and Contract IQ are cited as part of this cadence.

Profitability: Operating earnings are reported at nearly $3.9 billion for 2025, an all-time high. A record estimated 2026 policyowner dividend further signals strong underlying earnings capacity.

Strong Revenue Growth: Total sales surpassed $43 billion in 2025, up from 2024 levels. Company disclosures also indicate higher total revenue year over year.

Investor Backing & Capital Strength: Total adjusted capital increased to $34.4 billion in 2025, alongside affirmations of very high financial strength ratings from major agencies. These indicators are presented as continued balance-sheet resilience.

Profitability: Adjusted EBITDA and ex‑TAC gross profit are rising at double‑digit rates, with Q2 margins expanding and management raising full‑year profitability guidance. This points to increasing operating leverage even as mix shifts favor higher‑margin revenue.

Strategic Partnerships: A 30‑year exclusive native‑ads agreement with Yahoo is live globally and framed as a multi‑year growth driver with sizable revenue potential. Recent publisher wins such as Fox News further extend distribution that supports current results and the outlook.

Innovation-Driven Growth: Momentum in the Realize performance offering and AI initiatives like DeeperDive are cited as contributors to improved results and raised guidance. These offerings indicate continued product evolution beyond classic native formats.

Strong Revenue Growth: Revenue is reported to have grown 26% in FY2024, alongside roughly 30% ARR growth in 2023 after surpassing the $100M milestone in 2022. This indicates sustained top-line expansion across consecutive years.

Profitability: The company reports remaining profitable and cash‑flow positive while growing in FY2024. This suggests operational discipline alongside expansion.

Investor Backing & Capital Strength: A July 2024 majority investment led by Vista Equity Partners valued the company at about $1.2B, with participation from TCV and KKR. This financing signals external confidence and provides resources for further expansion.

Strategic Partnerships: The acquisition by Model N positions Kalderos’s 340B and gross-to-net capabilities inside a larger life-sciences revenue platform, implying broader distribution and customer access. Integration of the Truzo claims-level visibility into Model N’s suite signals strategic value and scale-up potential.

Strong Revenue Growth: Company materials state revenue more than doubled two years in a row leading into 2023, alongside expanding customers and team. These signals point to strong pre-acquisition traction that can be leveraged under Model N.

Market Expansion: 340B drug purchases reached roughly $66.3B in 2023, indicating a large and expanding market the combined offering serves. This category tailwind supports ongoing demand for discount-management and gross-to-net solutions.

Strong Revenue Growth: Total revenue increased 19% in FY2026 and 16% in Q1 FY2027, while ARR reached about $2.14B, up roughly 17% year over year. Net‑new ARR also accelerated, signaling strengthening demand.

Profitability: Non‑GAAP operating income was $592M in FY2026 with ~29% margin, and Q1 FY2027 reported a ~29% margin alongside robust adjusted free cash flow. Free cash flow for FY2026 was $529M, underscoring strong operating leverage.

Resilient & Sustainable Growth: Multi‑year double‑digit ARR and revenue expansion, record large deals, and 41% organic net‑new ARR growth in Q1 FY2027 point to durable demand. A subscription‑led model and fast‑growing logs consumption support ongoing platform adoption.

Strong Revenue Growth: Revenue rose 11% year over year in Q2 2026, while contribution ex‑TAC increased 17% and management raised full‑year 2026 growth targets. Recent periods also show steady gains, including FY2025 revenue up about 7% and contribution ex‑TAC up 10%.

Profitability: Adjusted EBITDA grew 30% year over year in Q2 2026 with a 37% margin, and net income increased to $19.4M from $11.1M. FY2025 adjusted EBITDA rose 18%, indicating expanding operating leverage.

Strong Market Position & Advantage: CTV momentum is supported by broad‑based publisher demand and SpringServe differentiation, with CTV contribution ex‑TAC up 36% to $97.1M and reaching 51% of total. Company materials consistently position the firm as the largest independent SSP and a top player in CTV.

Investor Backing & Capital Strength: Formation Bio closed a $372M Series D on June 26, 2024 led by a16z with significant participation from Sanofi, bringing total funding to over $600M and at a material step-up in valuation. The capital is directed toward expanding its drug pipeline and AI platform.

Strategic Partnerships: A first‑in‑class AI collaboration with Sanofi and OpenAI (announced May 2024) has already produced Muse, an AI tool for patient recruitment. Additional partnering activity includes Sanofi’s 2025 deal for gusacitinib via a Formation subsidiary, signaling expanding commercial and technology ties.

Product Line Growth: Multiple in‑licensing moves in 2025–2026 (e.g., a CNS‑penetrant TYK2 inhibitor, a miR‑124 activator, and an anti‑CD226 program) broaden the portfolio. The first participant was dosed in a Phase 1 trial (BLKR201) on June 9, 2026, marking concrete clinical progression.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Strong Market Position & Advantage: Repeated Leader placements in Gartner’s DEX Magic Quadrant (2024–2026) and Forrester’s 2024 EUEM Wave indicate durable competitive standing and sustained category momentum. These recognitions coincide with communications citing 1,200–1,500+ customers and 20M+ endpoints, underscoring broad enterprise adoption.

Product Line Growth: New offerings such as Adopt on Infinity (2025) and the Spark personal IT agent (2026), plus integrations like GoTo/Rescue and a government-focused AWS Marketplace listing, expand use cases and routes to market. The 2024 acquisition of AppLearn further broadened capabilities into digital adoption.

Investor Backing & Capital Strength: A late‑2025 majority investment by Vista Equity Partners at an approximately $3B valuation signals strong external confidence and provides resources for scaling. This step-up from the 2021 round supports continued product and go‑to‑market execution.

Market Expansion: A completed acquisition of Urgently and higher stated coverage—about 150 million drivers and roughly 14 million annual events versus lower figures in 2019–2020—indicate a larger footprint. Industry recognition and growth forecasts for roadside assistance provide supportive category tailwinds.

Strategic Partnerships: Multi-year renewals with Hagerty and long-standing OEM relationships such as Ford, plus wins in fleet/telematics channels (e.g., Geotab), signal retention and new routes to market. Additional insurer partnerships like Virginia Farm Bureau broaden channel access.

Product Line Growth: Crash Response deployments expanded after significant 2023 gains, with calls up sharply since launch and dispatch volumes doubling as more top carriers adopted the service. Emphasis on the Swoop platform and automation supports continued product-led scaling.

Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.

Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.

Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.

Investor Backing & Capital Strength: Funding milestones include a $71M Series C in February 2022 and total disclosed capital of about $114.5M, with backers such as Accel, Insight Partners, and Tiger Global. This capital base supports multi‑year scaling while the company continues executing without a newly announced post‑2022 round.

Innovation-Driven Growth: Product expansion since 2024 centers on AI-focused capabilities such as measuring the impact of AI coding tools, the AI Impact Dashboard (2024), and a smarter Jellyfish Assistant (March 2026). Partnerships (e.g., Augment Code) and ongoing research outputs (e.g., the 2026 State of Engineering Management) indicate an active roadmap aligned to emerging demand.

Strong Market Position & Advantage: Recognition includes placement as a Leader in Gartner’s inaugural 2026 Magic Quadrant for Developer Productivity Insight Platforms and sustained Leader status on G2’s Software Development Analytics Tools grid through 2026. Case studies with well-known brands and broader availability via AWS Marketplace (since 2023) reinforce category presence.

Investor Backing & Capital Strength: Strategic investment backing is positioned as growth-oriented support, with Vista Equity Partners described as making a strategic growth investment to help scale the platform.

Innovation-Driven Growth: Product expansion is framed around adding new capabilities, including the acquisition of Jebbit and embedding no-code interactive experiences to capture zero-/first-party data natively in the platform.

Strong Brand Reputation: Market recognition is portrayed as solid, with analyst placements like Strong Performer/Challenger in certain evaluations and references to award recognition and notable brand usage.